NCT06234137招募中不适用
A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrotinib in the Treatment of Local-advanced HER2-positive Breast Cancer
Wang Ouchen1 个研究点 分布在 1 个国家目标入组 154 人开始时间: 2021年11月27日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 154
- 试验地点
- 1
- 主要终点
- tpCR
研究概览
简要总结
This study is a prospective, open, multi-center, single arm trial. The treatment group will receive six cycles of docetaxel, carboplatin combined with Inetetamab and Pyrotinib before surgery. By focusing on tpCR (ypT0/is, ypN0) evaluated by pathology, the efficacy of docetaxel, carboplatin combined with Inetetamab and Pyrotinib in the preoperative treatment of locally advanced HER2-positive breast cancer will be evaluated. During long-term follow-up, event-free survival (EFS), disease-free survival (DFS), distant metastasis-free survival (DDFS), overall survival (OS), central nervous system disease-free survival (CNSDFS) under this treatment regimen will be evaluated, and the efficacy-related biomarkers will be explored. The cardiotoxicity of Inetetamab and Pyrotinib in the treatment of breast cancer is also be evaluated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Female patients aged 18-75 years old;
- •ECOG score 0-1;
- •Breast cancer meets the following criteria: Histologically confirmed invasive breast cancer, primary tumor diameter > 2 cm as determined by standard evaluation methods at the research center; tumor stage: locally advanced;
- •HER2 expression-positive breast cancer confirmed by pathological examination;
- •Known hormone receptor status (ER and PR);
- •The functional level of major organs must meet the following requirements (no blood transfusion within 2 weeks before screening, no use of white blood cell and platelet-raising drugs):
- •(1) Blood routine: neutrophil (ANC) >= 1.5×10^9/L; platelet count (PLT) >= 90×10^9/L; hemoglobin (Hb) >= 90 g/L; (2) Blood biochemistry: total bilirubin (TBIL) <= upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <= 1.5×ULN; alkaline phosphatase <= 2.5×ULN; urea nitrogen (BUN) and creatinine (Cr) <= 1.5×ULN; (3) Echocardiography: left ventricular ejection fraction (LVEF) >= 60%; (4) 12-lead ECG: Fridericia-corrected QT interval (QTcF) < 470 msec;
- •Female patients who are not menopausal or surgically sterilized: agree to abstain from sex or use effective contraceptive methods during treatment and for at least 7 months after the last dose in the study treatment;
- •Voluntarily join the study, sign the informed consent, have good compliance and are willing to cooperate with follow-up.
排除标准
- •IV (metastatic) breast cancer;
- •Received anti-tumor therapy or radiotherapy for any malignant tumor in the past, excluding cured cervical carcinoma in situ, basal cell carcinoma or squamous cell carcinoma and other malignant tumors;
- •Receiving anti-tumor therapy in other clinical trials at the same time, including endocrine therapy, bisphosphonate therapy or immunotherapy;
- •Received major surgical operations unrelated to breast cancer within 4 weeks before enrollment, or the patient has not fully recovered from such surgical operations;
- •Severe cardiac disease or discomfort, including but not limited to the following: a history of heart failure or systolic dysfunction (LVEF < 60%); high-risk uncontrolled arrhythmias, such as atrial tachycardia, resting heart rate > 100 bpm , significant ventricular arrhythmia (eg, ventricular tachycardia) or higher-grade AV block (ie, Mobitz II second-degree AV block or third-degree AV block); antianginal medication indicated angina pectoris; clinically significant heart valve disease; transmural myocardial infarction on ECG; poorly controlled hypertension (systolic > 180 mmHg and/or diastolic > 100 mmHg);
- •Inability to swallow, intestinal obstruction, or other factors that affect drug taking and absorption;
- •Those who are known to have a history of allergy to the drug components of this regimen; have a history of immunodeficiency, including HIV positive test, or have other acquired or congenital immunodeficiency diseases, or have a history of organ transplantation;
- •Female patients during pregnancy and lactation, female patients with fertility and positive baseline pregnancy test, or patients of childbearing age who are unwilling to take effective contraceptive measures during the entire trial period and within 7 months after the last study drug;
- •Have serious comorbidities or other comorbidities that would interfere with planned treatment, or any other condition that the investigator considers the patient unsuitable to participate in this study.
研究组 & 干预措施
treatment arm
Experimental
干预措施: Docetaxel (Drug)
treatment arm
Experimental
干预措施: Carboplatin (Drug)
treatment arm
Experimental
干预措施: Inetetamab (Drug)
treatment arm
Experimental
干预措施: Pyrotinib (Drug)
结局指标
主要结局
tpCR
时间窗: Approximately 5 months from randomization following surgery or early withdrawal, whichever occurred first (Surgery was performed within 2 weeks after Cycle 6)
total pathological complete response
次要结局
- DDFS(Randomization up to a maximum of 329 weeks)
- EFS(Randomization up to a maximum of 329 weeks)
- DFS(Randomization up to a maximum of 329 weeks)
- OS(Up to 2 years)
- CNS-DFS(Randomization up to a maximum of 329 weeks)
研究者
Wang Ouchen
Chief Physician
First Affiliated Hospital of Wenzhou Medical University
研究点 (1)
Loading locations...
相似试验
已完成
不适用
BIONICS 38 mm Trial EluNIR Ridaforolimus Eluting Coronary Stent System (EluNIR) In Coronary Stenosis TrialCoronary StenosisNCT03702608Medinol Ltd.50
招募中
3 期
Nimotuzumab in Combined With Chemoradiotherapy to Treat the Newly Diagnosed Diffuse Intrinsic Pontine Glioma in ChildrenDiffuse Intrinsic Pontine GliomaNCT04532229Biotech Pharmaceutical Co., Ltd.48
招募中
4 期
Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast CancerSolid TumorNCT05525767Hebei Medical University Fourth Hospital75
招募中
2 期
Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Cancer: A Multicenter StudyMuscle Invasive Bladder Cancer Urothelial CarcinomaNCT05328336Tianjin Medical University Second Hospital74
尚未招募
2 期
Study to Evaluate the Efficacy of Afatinib in Skull Base ChordomaChordoma of ClivusNCT05519917Huashan Hospital20